| Targeting osteopontin suppresses glioblastoma stem‐like cell character and tumorigenicity in vivo V Lamour, A Henry, J Kroonen, MJ Nokin, Z von Marschall, LW Fisher, ... International journal of cancer 137 (5), 1047-1057, 2015 | 62 | 2015 |
| Predictors of neutralizing antibody response to BNT162b2 vaccination in allogeneic hematopoietic stem cell transplant recipients L Canti, S Humblet-Baron, I Desombere, J Neumann, P Pannus, ... Journal of hematology & oncology 14, 1-12, 2021 | 47 | 2021 |
| HDAC7 inhibition resets STAT3 tumorigenic activity in human glioblastoma independently of EGFR and PTEN: new opportunities for selected targeted therapies P Peixoto, A Blomme, B Costanza, R Ronca, S Rezzola, AP Palacios, ... Oncogene 35 (34), 4481-4494, 2016 | 35 | 2016 |
| Antibody response against SARS-CoV-2 Delta and Omicron variants after third-dose BNT162b2 vaccination in allo-HCT recipients L Canti, KK Ariën, I Desombere, S Humblet-Baron, P Pannus, ... Cancer Cell 40 (4), 335-337, 2022 | 22 | 2022 |
| Les protéines SIBLING V Lamour, MJ Nokin, A Henry, V Castronovo, A Bellahcène médecine/sciences 29, 1018-25, 2013 | 18 | 2013 |
| New role of osteopontin in DNA repair and impact on human glioblastoma radiosensitivity A Henry, MJ Nokin, N Leroi, F Lallemand, J Lambert, N Goffart, ... Oncotarget 7 (39), 63708, 2016 | 15 | 2016 |
| Respiratory multiplex PCR and procalcitonin to reduce antibiotic exposure in severe SARS-CoV-2 pneumonia: A multicentre randomized controlled trial M Fartoukh, S Nseir, B Mégarbane, Y Cohen, A Lafarge, D Contou, ... Clinical Microbiology and Infection 29 (6), 734-743, 2023 | 10 | 2023 |
| I-Kappa-B kinase-epsilon activates nuclear factor-kappa B and STAT5B and supports glioblastoma growth but amlexanox shows little therapeutic potential in these tumors N Dubois, S Berendsen, A Henry, M Nguyen, V Bours, P Robe Cancer Translational Medicine 4 (1), 2018 | 2 | 2018 |
| Clinical phenotypes and outcomes associated with SARS-CoV-2 Omicron variants BA. 2, BA. 5 and BQ. 1.1 in critically ill patients with COVID-19: a prospective, multicenter … N de Prost, E Audureau, S Préau, R Favory, A Guigon, P Bay, N Heming, ... Intensive Care Medicine Experimental 11 (1), 48, 2023 | 1 | 2023 |
| Limited Effects of Class II Transactivator-Based Immunotherapy in Murine and Human Glioblastoma AK Tan, A Henry, N Goffart, S van Logtestijn, V Bours, EM Hol, PA Robe Cancers 16 (1), 193, 2023 | | 2023 |
| Clinical phenotypes and outcomes associated with SARS-CoV-2 variant Omicron, sublineages BA. 1, BA. 1.1, BA. 2 and impact of mutational patterns in critically ill French … N de Prost, E Audureau, N Heming, E Gault, T Pham, A Chaghouri, ... | | 2022 |
| Third-dose BNT162b2 vaccine is highly efficient at increasing anti-rbd sars-cov-2 igg titers in allo-hct recipients L Canti, S Humblet-Baron, I Desombere, P Pannus, A Henry, S Servais, ... Bone Marrow Transplantation, 280-280, 2022 | | 2022 |
| Managing nausea and vomiting in pregnancy in a primary care setting (vol 45, pg 564, 2016) A Tan, T Foran, A Henry AUSTRALIAN FAMILY PHYSICIAN 45 (9), 619-619, 2016 | | 2016 |
| Rôle de l'ostéopontine dans la progression et la radiorésistance des glioblastomes humains. A Henry | | 2016 |
| Osteopontin predicts radiotherapy response of glioblastoma patients: new role in DNA damage repair A Henry, MJ Nokin, N Leroi, F LALLEMAND, J Lambert, N Goffart, ... 3rd Symposium on small animal precision image-guided radiotherapy, 2016 | | 2016 |
| Osteopontin as a new target in glioblastoma progression and resistance to radiotherapy A Henry, A Bellahcene, V Castronovo, P Peixoto, N Goffart, F Lallemand, ... II International Symposium on clinical and basic investigation in glioblastoma, 2015 | | 2015 |
| Recommend this article JP Henry, L Monition La Houille Blanche 2 (3), 209-218, 1982 | | 1982 |
